ESMO Guidelines for Chronic
Lymphocytic Leukemia Exam
Review Questions and Answers
Bruton tyrosine kinase inhibitors (BTKis) - Answer-Drugs targeting Bruton tyrosine
kinase for CLL.
hazard ratio (HR) - Answer-Statistical measure of treatment effect risk.
ELEVATE study - Answer-Research comparing acalabrutinib and chlorambucil in CLL.
FCR - Answer-Fludarabine, cyclophosphamide, and rituximab regimen.
BR - Answer-Bendamustine plus rituximab combination therapy.
crossover trial - Answer-Study allowing patients to switch treatments.
OS - Answer-Overall survival duration of patients.
time-limited therapy - Answer-Treatment administered for a defined period.
continuous treatment - Answer-Ongoing therapy until disease progression.
phase III trial - Answer-Advanced clinical trial assessing treatment efficacy.
subgroup analyses - Answer-Evaluation of treatment effects in specific patient groups.
Subgroup analysis - Answer-Evaluation of treatment effects in specific patient groups.
CLL14 trial - Answer-Study comparing venetoclax plus obinutuzumab versus CIT.
TP53 mutation - Answer-Genetic alteration affecting treatment efficacy in CLL.
PI3K inhibitor - Answer-Drug class targeting phosphoinositide 3-kinase pathway.
Idelalisib - Answer-PI3K inhibitor used with rituximab in CLL.
Symptomatic patients - Answer-Patients exhibiting clinical symptoms of disease.
, BCRi - Answer-B-cell receptor inhibitors like ibrutinib.
Continuous medication - Answer-Ongoing treatment without interruption.
Therapeutic regimen change - Answer-Modifying treatment based on disease response.
Venetoclax plus rituximab - Answer-Combination therapy for 24 months in CLL.
Acalabrutinib - Answer-Another BTK inhibitor option for CLL treatment.
Asymptomatic CLL - Answer-Chronic lymphocytic leukemia without noticeable
symptoms.
IGHV mutation - Answer-Genetic alteration influencing CLL treatment outcomes.
HR - Answer-Hazard ratio, comparing risks between treatment groups.
TLS - Answer-Tumor lysis syndrome, a potential treatment complication.
Ramp-up period - Answer-Gradual increase in medication dosage to minimize side
effects.
Secondary neoplasia - Answer-New cancers arising as a treatment complication.
Cardiovascular disorders - Answer-Heart-related conditions affecting treatment
decisions.
FCR therapy - Answer-Combination of fludarabine, cyclophosphamide, and rituximab.
BR therapy - Answer-Bendamustine and rituximab for fit patients over 65.
BTKis - Answer-Bruton tyrosine kinase inhibitors for CLL treatment.
alloSCT - Answer-Allogeneic stem cell transplantation for CLL patients.
autoSCT - Answer-Autologous stem cell transplantation not useful in CLL.
HCT-CI score - Answer-Haematopoietic cell transplant comorbidity index score.
CAR-T cells - Answer-Chimeric antigen receptor T cells for CLL treatment.
BiTE antibodies - Answer-Bi-specific T-cell engagers targeting CLL cells.
Symptomatic relapsed CLL - Answer-CLL that has returned after initial treatment.
Short remission duration - Answer-Remission lasting less than 36 months.
Lymphocytic Leukemia Exam
Review Questions and Answers
Bruton tyrosine kinase inhibitors (BTKis) - Answer-Drugs targeting Bruton tyrosine
kinase for CLL.
hazard ratio (HR) - Answer-Statistical measure of treatment effect risk.
ELEVATE study - Answer-Research comparing acalabrutinib and chlorambucil in CLL.
FCR - Answer-Fludarabine, cyclophosphamide, and rituximab regimen.
BR - Answer-Bendamustine plus rituximab combination therapy.
crossover trial - Answer-Study allowing patients to switch treatments.
OS - Answer-Overall survival duration of patients.
time-limited therapy - Answer-Treatment administered for a defined period.
continuous treatment - Answer-Ongoing therapy until disease progression.
phase III trial - Answer-Advanced clinical trial assessing treatment efficacy.
subgroup analyses - Answer-Evaluation of treatment effects in specific patient groups.
Subgroup analysis - Answer-Evaluation of treatment effects in specific patient groups.
CLL14 trial - Answer-Study comparing venetoclax plus obinutuzumab versus CIT.
TP53 mutation - Answer-Genetic alteration affecting treatment efficacy in CLL.
PI3K inhibitor - Answer-Drug class targeting phosphoinositide 3-kinase pathway.
Idelalisib - Answer-PI3K inhibitor used with rituximab in CLL.
Symptomatic patients - Answer-Patients exhibiting clinical symptoms of disease.
, BCRi - Answer-B-cell receptor inhibitors like ibrutinib.
Continuous medication - Answer-Ongoing treatment without interruption.
Therapeutic regimen change - Answer-Modifying treatment based on disease response.
Venetoclax plus rituximab - Answer-Combination therapy for 24 months in CLL.
Acalabrutinib - Answer-Another BTK inhibitor option for CLL treatment.
Asymptomatic CLL - Answer-Chronic lymphocytic leukemia without noticeable
symptoms.
IGHV mutation - Answer-Genetic alteration influencing CLL treatment outcomes.
HR - Answer-Hazard ratio, comparing risks between treatment groups.
TLS - Answer-Tumor lysis syndrome, a potential treatment complication.
Ramp-up period - Answer-Gradual increase in medication dosage to minimize side
effects.
Secondary neoplasia - Answer-New cancers arising as a treatment complication.
Cardiovascular disorders - Answer-Heart-related conditions affecting treatment
decisions.
FCR therapy - Answer-Combination of fludarabine, cyclophosphamide, and rituximab.
BR therapy - Answer-Bendamustine and rituximab for fit patients over 65.
BTKis - Answer-Bruton tyrosine kinase inhibitors for CLL treatment.
alloSCT - Answer-Allogeneic stem cell transplantation for CLL patients.
autoSCT - Answer-Autologous stem cell transplantation not useful in CLL.
HCT-CI score - Answer-Haematopoietic cell transplant comorbidity index score.
CAR-T cells - Answer-Chimeric antigen receptor T cells for CLL treatment.
BiTE antibodies - Answer-Bi-specific T-cell engagers targeting CLL cells.
Symptomatic relapsed CLL - Answer-CLL that has returned after initial treatment.
Short remission duration - Answer-Remission lasting less than 36 months.
